Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710652 | 0.83 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL805047 | 0.83 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL800240 | 0.82 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL800696 | 0.82 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL10280341 | 0.81 | POLB (0.51) | POLBMEN1USP2KMT2AP2RY12 | |
| SCHEMBL882310 | 0.76 | TSHR (0.36) | — | |
| SCHEMBL13190375 | 0.75 | ABCB1 (0.34) | KMT2A | |
| SCHEMBL13190552 | 0.75 | ABCB1 (0.34) | KMT2A | |
| SCHEMBL5547205 | 0.75 | MEN1 (0.58) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL12473580 | 0.75 | MEN1 (0.58) | POLBMEN1USP2KMT2AP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |